(NASDAQ: ORGO) Organogenesis Holdings's forecast annual revenue growth rate of 13.79% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 3.8%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.57%.
Organogenesis Holdings's revenue in 2025 is $458,760,000.On average, 1 Wall Street analysts forecast ORGO's revenue for 2025 to be $64,247,637,231, with the lowest ORGO revenue forecast at $64,247,637,231, and the highest ORGO revenue forecast at $64,247,637,231. On average, 1 Wall Street analysts forecast ORGO's revenue for 2026 to be $74,302,429,055, with the lowest ORGO revenue forecast at $74,302,429,055, and the highest ORGO revenue forecast at $74,302,429,055.
In 2027, ORGO is forecast to generate $87,522,089,749 in revenue, with the lowest revenue forecast at $87,522,089,749 and the highest revenue forecast at $87,522,089,749.